Publications 2024

Asadi-Pooya AA, Johannessen Landmark C, Mirzaei Damabi N, Fazelian K (2024)
Interactions between antiseizure medications and foods and drinks: A systematic review
Epilepsia Open, 9 (2), 475-485
DOI 10.1002/epi4.12918, PubMed 38345419

Publications 2023

Cockerell I, Christensen J, Hoei-Hansen CE, Holst L, Grenaa Frederiksen M, Issa-Epe AI, Nedregaard B, Solhoff R, Heimdal K, Johannessen Landmark C, Lund C, Nærland T (2023)
Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice
Orphanet J Rare Dis, 18 (1), 377
DOI 10.1186/s13023-023-02982-1, PubMed 38042867

Heger K, Kjeldstadli K, Ring N, Aaberg KM, Kjeldsen SF, Burns ML, Johannessen SI, Johannessen Landmark C (2023)
Pharmacokinetic Variability of Sulthiame: The Impact of Age, Drug-Drug Interactions, and Biochemical Markers of Toxicity in Patients with Epilepsy
Ther Drug Monit, 46 (2), 237-245
DOI 10.1097/FTD.0000000000001146, PubMed 38158595

Johannessen Landmark C, Eyal S, Burns ML, Franco V, Johannessen SI (2023)
Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring
Epileptic Disord, 25 (4), 454-471
DOI 10.1002/epd2.20069, PubMed 37259844

Palmisani M, Tartara E, Johannessen Landmark C, Crema F, De Giorgis V, Varesio C, Fattore C, Rota P, Russo E, Franco V (2023)
Therapeutic Salivary Monitoring of Perampanel in Patients with Epilepsy Using a Volumetric Absorptive Microsampling Technique
Pharmaceutics, 15 (8)
DOI 10.3390/pharmaceutics15082030, PubMed 37631244

Pedersen S, Kverneland M, Rudi K, Gervin K, Landmark CJ, Iversen PO, Selmer KK (2023)
Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet
Epilepsia Open, 8 (3), 858-866
DOI 10.1002/epi4.12746, PubMed 37057954

Publications 2022

Heger K, Skipsfjord J, Kiselev Y, Burns ML, Aaberg KM, Johannessen SI, Skurtveit S, Johannessen Landmark C (2022)
Changes in the use of antiseizure medications in children and adolescents in Norway, 2009-2018
Epilepsy Res, 181, 106872
DOI 10.1016/j.eplepsyres.2022.106872, PubMed 35180640

Henning O, Alfstad KÅ, Johannessen Landmark C, Helmstaedter C, Lossius MI, Holth Skogan A (2022)
Use of screening tools to assess comorbidities and adverse events in patients with epilepsy. A European Reference Network for Rare and Complex Epilepsies (EpiCARE) survey
Seizure, 101, 237-243
DOI 10.1016/j.seizure.2022.09.008, PubMed 36115293

Larsen RE, Pripp AH, Krogstad T, Johannessen Landmark C, Holm LB (2022)
Development and validation of a new non-disease-specific survey tool to assess self-reported adherence to medication
Front Pharmacol, 13, 981368
DOI 10.3389/fphar.2022.981368, PubMed 36569319

Larsson D, Baftiu A, Johannessen Landmark C, von Euler M, Kumlien E, Åsberg S, Zelano J (2022)
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy
JAMA Neurol, 79 (2), 169-175
DOI 10.1001/jamaneurol.2021.4584, PubMed 34902006

Revdal E, Morken G, Bakken IJ, Bråthen G, Landmark CJ, Brodtkorb E (2022)
Bidirectionality of antiseizure and antipsychotic treatment: A population-based study
Epilepsy Behav, 136, 108911
DOI 10.1016/j.yebeh.2022.108911, PubMed 36126553

Svendsen T, Brodtkorb E, Linge HL, Burns ML, Johannessen SI, Nakken KO, Lossius MI, Landmark CJ (2022)
Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy
Epilepsy Res, 183, 106946
DOI 10.1016/j.eplepsyres.2022.106946, PubMed 35609355

Publications 2021

Baumgartner T, Carreño M, Rocamora R, Bisulli F, Boni A, Brázdil M, Horak O, Craiu D, Pereira C, Guerrini R, San Antonio-Arce V, Schulze-Bonhage A, Zuberi SM, Hallböök T, Kalviainen R, Lagae L, Nguyen S, Quintas S, Franco A, Cross JH, Walker M, Arzimanoglou A, Rheims S, Granata T, Canafoglia L et al. (2021)
A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies
Epilepsia Open, 6 (1), 160-170
DOI 10.1002/epi4.12459, PubMed 33681659

Johannessen Landmark C, Potschka H, Auvin S, Wilmshurst JM, Johannessen SI, Kasteleijn-Nolst Trenité D, Wirrell EC (2021)
The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results
Epilepsia, 62 (4), 857-873
DOI 10.1111/epi.16849, PubMed 33638459

Landmark CJ, Rektorli L, Burns ML, Revdal E, Johannessen SI, Brodtkorb E (2021)
Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation
Epileptic Disord, 23 (2), 426-431
DOI 10.1684/epd.2021.1273, PubMed 33935028

Mochol M, Whatmore P, Taubøll E, Landmark CJ, Ropstad E, Svalheim S, Fraser TWK (2021)
Lamotrigine effects on immune gene expression in larval zebrafish
Epilepsy Res, 178, 106823
DOI 10.1016/j.eplepsyres.2021.106823, PubMed 34844088

Publications 2020

Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, The Cannabinoids International Experts Panel, Collaborators (2020)
Epilepsy and cannabidiol: a guide to treatment
Epileptic Disord, 22 (1), 1-14
DOI 10.1684/epd.2020.1141, PubMed 32096470

Franco V, Gatti G, Mazzucchelli I, Marchiselli R, Fattore C, Rota P, Galimberti CA, Capovilla G, Beccaria F, De Giorgis V, Johannessen Landmark C, Perucca E (2020)
Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy
Epilepsia, 61 (7), e79-e84
DOI 10.1111/epi.16584, PubMed 32562438

Heger K, Lund C, Larsen Burns M, Bjørnvold M, Sætre E, Johannessen SI, Johannessen Landmark C (2020)
A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
Epilepsia Open, 5 (3), 432-441
DOI 10.1002/epi4.12413, PubMed 32913951

Johannessen Landmark C, Heger K, Lund C, Burns ML, Bjørnvold M, Sætre E, Johannessen SI (2020)
Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome
Ther Drug Monit, 42 (5), 744-753
DOI 10.1097/FTD.0000000000000781, PubMed 32558674

Johannessen Landmark C, Johannessen SI, Patsalos PN (2020)
Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects
Expert Opin Drug Metab Toxicol, 16 (3), 227-238
DOI 10.1080/17425255.2020.1724956, PubMed 32054370

Landmark CJ, Brandl U (2020)
Pharmacology and drug interactions of cannabinoids
Epileptic Disord, 22 (S1), 16-22
DOI 10.1684/epd.2019.1123, PubMed 31941642

Svendsen T, Brodtkorb E, Baftiu A, Lossius MI, Nakken KO, Johannessen SI, Johannessen Landmark C (2020)
Clinical experience combined with therapeutic drug monitoring of lacosamide
Acta Neurol Scand, 141 (4), 279-286
DOI 10.1111/ane.13206, PubMed 31853958

Publications 2019

Alvestad S, Bjørnvold M, Molteberg E, Lossius M, Landmark CJ (2019)
[Continued importance of valproate for women with generalised epilepsy]
Tidsskr Nor Laegeforen, 139 (7)
DOI 10.4045/tidsskr.19.0220, PubMed 30969058

Baftiu A, Lima MH, Svendsen K, Larsson PG, Johannessen SI, Landmark CJ (2019)
Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation
Eur J Clin Pharmacol, 75 (8), 1153-1160
DOI 10.1007/s00228-019-02678-1, PubMed 31001654

Granas AG, Halvorsen KH, Wendelbo J, Johannessen Landmark C (2019)
Interdisciplinary medication review to improve pharmacotherapy for patients with intellectual disabilities
Int J Clin Pharm, 41 (6), 1516-1525
DOI 10.1007/s11096-019-00914-3, PubMed 31729635

Henning O, Johannessen Landmark C, Nakken KO, Lossius MI (2019)
Nonadherence to treatment regimens in epilepsy from the patient's perspective and predisposing factors: Differences between intentional and unintentional lack of adherence
Epilepsia, 60 (5), e58-e62
DOI 10.1111/epi.14734, PubMed 30980675

Henning O, Johannessen Landmark C, Traeen B, Svendsen T, Farmen A, Nakken KO, Lossius M (2019)
Sexual function in people with epilepsy: Similarities and differences with the general population
Epilepsia, 60 (9), 1984-1992
DOI 10.1111/epi.16311, PubMed 31407332

Henning O, Landmark CJ, Henning D, Nakken KO, Lossius MI (2019)
Challenges in epilepsy-The perspective of Norwegian epilepsy patients
Acta Neurol Scand, 140 (1), 40-47
DOI 10.1111/ane.13098, PubMed 30963535

Henning O, Lossius MI, Lima M, Mevåg M, Villagran A, Nakken KO, Johannessen Landmark C (2019)
Refractory epilepsy and nonadherence to drug treatment
Epilepsia Open, 4 (4), 618-623
DOI 10.1002/epi4.12367, PubMed 31819918

Johannessen Landmark C, Fløgstad I, Baftiu A, Syvertsen M, Enger U, Koht J, Johannessen SI (2019)
Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy
Epilepsy Res, 155, 106148
DOI 10.1016/j.eplepsyres.2019.05.016, PubMed 31195184

Johannessen Landmark C, Fløgstad I, Syvertsen M, Baftiu A, Enger U, Koht J, Johannessen SI (2019)
Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy
Epilepsy Behav, 98 (Pt A), 110-116
DOI 10.1016/j.yebeh.2019.05.021, PubMed 31330379

Larsen Burns M, Kinge E, Stokke Opdal M, Johannessen SI, Johannessen Landmark C (2019)
Therapeutic drug monitoring of gabapentin in various indications
Acta Neurol Scand, 139 (5), 446-454
DOI 10.1111/ane.13075, PubMed 30710348

Larsen Burns M, Nikanorova M, Baftiu A, Borg Rasmussen J, Johannessen SI, Johannessen Landmark C (2019)
Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway
Ther Drug Monit, 41 (3), 340-347
DOI 10.1097/FTD.0000000000000599, PubMed 30688870

Publications 2018

Johannessen Landmark C, Farmen AH, Burns ML, Baftiu A, Lossius MI, Johannessen SI, Tomson T (2018)
Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring
Epilepsy Res, 141, 31-37
DOI 10.1016/j.eplepsyres.2018.02.004, PubMed 29453075

Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C (2018)
Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines
Drug Des Devel Ther, 12, 271-280
DOI 10.2147/DDDT.S154388, PubMed 29467570

Syvertsen M, Fløgstad I, Enger U, Landmark CJ, Koht J (2018)
Antiepileptic drug withdrawal in juvenile myoclonic epilepsy
Acta Neurol Scand, 139 (2), 192-198
DOI 10.1111/ane.13042, PubMed 30378684

Publications 2017

Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, Granas AG, Johannessen SI, Landmark CJ (2017)
Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015
Epilepsy Res, 139, 35-42
DOI 10.1016/j.eplepsyres.2017.11.001, PubMed 29175562

Baftiu A, Landmark CJ, Rusten IR, Feet SA, Johannessen SI, Larsson PG (2017)
Erratum to: Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-A pharmacoepidemiological study and clinical implications
Eur J Clin Pharmacol, 73 (6), 791-792
DOI 10.1007/s00228-017-2252-0, PubMed 28389679

Johannessen Landmark C, Burns ML, Baftiu A, Farmen AH, Lossius MI, Johannessen SI, Tomson T (2017)
Pharmacokinetic variability of valproate in women of childbearing age
Epilepsia, 58 (10), e142-e146
DOI 10.1111/epi.13872, PubMed 28833045

Pisani LR, Nikanorova M, Landmark CJ, Johannessen SI, Pisani F (2017)
Specific Patient Features Affect Antiepileptic Drug Therapy Decisions: Focus on Gender, Age, and Psychiatric Comorbidities
Curr Pharm Des, 23 (37), 5639-5648
DOI 10.2174/1381612823666170926103631, PubMed 28950817

Reimers A, Berg JA, Burns ML, Landmark CJ (2017)
Harmonised reference ranges for antiepileptic drugs
Tidsskr Nor Laegeforen, 137 (12-13), 864-865
DOI 10.4045/tidsskr.17.0392, PubMed 28655236

Reimers A, Berg JA, Burns ML, Landmark CJ (2017)
Common reference range for antiepileptics
Tidsskr. Nor. Laegeforen., 137 (12-13), 864-865

Svendsen T, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI, Johannessen Landmark C (2017)
Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability
Neurochem Res, 42 (7), 2077-2083
DOI 10.1007/s11064-017-2234-8, PubMed 28349359

Publications 2016

Baftiu A, Johannessen Landmark C, Rusten IR, Feet SA, Johannessen SI, Larsson PG (2016)
Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications
Eur J Clin Pharmacol, 72 (10), 1245-1254
DOI 10.1007/s00228-016-2092-3, PubMed 27411937

Burns ML, Baftiu A, Opdal MS, Johannessen SI, Landmark CJ (2016)
Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability
Ther Drug Monit, 38 (3), 350-7
DOI 10.1097/FTD.0000000000000272, PubMed 26751267

Halvorsen KH, Johannessen Landmark C, Granas AG (2016)
Prevalence of Different Combinations of Antiepileptic Drugs and CNS Drugs in Elderly Home Care Service and Nursing Home Patients in Norway
Epilepsy Res Treat, 2016, 5153093
DOI 10.1155/2016/5153093, PubMed 27525114

Johannessen Landmark C, Henning O, Johannessen SI (2016)
Proconvulsant effects of antidepressants - What is the current evidence?
Epilepsy Behav, 61, 287-291
DOI 10.1016/j.yebeh.2016.01.029, PubMed 26926001

Johannessen Landmark C, Svendsen T, Dinarevic J, Kufaas RF, Reimers A, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI (2016)
The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice
Ther Drug Monit, 38 (4), 499-505
DOI 10.1097/FTD.0000000000000306, PubMed 27414974

Landmark CJ, Johannessen SI, Tomson T (2016)
Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring
Epileptic Disord, 18 (4), 367-383
DOI 10.1684/epd.2016.0880, PubMed 27965183

Mevaag M, Henning O, Baftiu A, Granas AG, Johannessen SI, Nakken KO, Johannessen Landmark C (2016)
Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs
Acta Neurol Scand, 135 (1), 80-87
DOI 10.1111/ane.12578, PubMed 26923477

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Johannessen Landmark C (2016)
Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome
Epilepsy Res, 129, 125-131
DOI 10.1016/j.eplepsyres.2016.12.001, PubMed 28043062

Publications 2015

Baftiu A, Johannessen Landmark C, Nikaj V, Neslein IL, Johannessen SI, Perucca E (2015)
Availability of antiepileptic drugs across Europe
Epilepsia, 56 (12), e191-7
DOI 10.1111/epi.13210, PubMed 26477534

Beiske GA, Holmøy T, Beiske AG, Johannessen SI, Johannessen Landmark C (2015)
Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis
Mult Scler Int, 2015, 317859
DOI 10.1155/2015/317859, PubMed 26221541

Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI (2015)
Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice
Seizure, 28, 88-91
DOI 10.1016/j.seizure.2015.02.017, PubMed 25758302

Johannessen Landmark C, I Johannessen S (2015)
Pharmacotherapy in epilepsy - does gender affect safety?
Expert Opin Drug Saf, 15 (1), 1-4
DOI 10.1517/14740338.2016.1117606, PubMed 26650146

Publications 2013

Henning O, Baftiu A, Johannessen SI, Landmark CJ (2013)
Withdrawal of antiepileptic drugs during presurgical video-EEG monitoring: an observational study for evaluation of current practice at a referral center for epilepsy
Acta Neurol Scand, 129 (4), 243-51
DOI 10.1111/ane.12179, PubMed 23980664

Karouni M, Henning O, Larsson PG, Johannessen SI, Johannessen Landmark C (2013)
Pharmacological treatment of psychiatric comorbidity in patients with refractory epilepsy
Epilepsy Behav, 29 (1), 77-81
DOI 10.1016/j.yebeh.2013.06.031, PubMed 23939032

Korczyn AD, Schachter SC, Brodie MJ, Dalal SS, Engel J, Guekht A, Hecimovic H, Jerbi K, Kanner AM, Johannessen Landmark C, Mares P, Marusic P, Meletti S, Mula M, Patsalos PN, Reuber M, Ryvlin P, Štillová K, Tuchman R, Rektor I (2013)
Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)
Epilepsy Behav, 28 (2), 283-302
DOI 10.1016/j.yebeh.2013.03.012, PubMed 23764496

Sørgaard G, Landmark CJ (2013)
[Electronic prescriptions and cooperation]
Tidsskr Nor Laegeforen, 133 (2), 133
DOI 10.4045/tidsskr.12.1471, PubMed 23344589

Tomson T, Landmark CJ, Battino D (2013)
Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications
Epilepsia, 54 (3), 405-14
DOI 10.1111/epi.12109, PubMed 23360413

Publications 2012

Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, Johannessen SI (2012)
Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication
Ther Drug Monit, 34 (4), 440-5
DOI 10.1097/FTD.0b013e31825ee389, PubMed 22777154

Johannessen Landmark C, Patsalos PN (2012)
Methodologies used to identify and characterize interactions among antiepileptic drugs
Expert Rev Clin Pharmacol, 5 (3), 281-92
DOI 10.1586/ecp.12.10, PubMed 22697591

Publications 2011

Johannessen Landmark C, Johannessen SI, Tomson T (2011)
Host factors affecting antiepileptic drug delivery-pharmacokinetic variability
Adv Drug Deliv Rev, 64 (10), 896-910
DOI 10.1016/j.addr.2011.10.003, PubMed 22063021

Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI (2011)
[The prescription registry and abuse of pregabalin]
Tidsskr Nor Laegeforen, 131 (3), 223
DOI 10.4045/tidsskr.10.1328, PubMed 21304565

Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI (2011)
Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population
Epilepsy Res, 95 (1-2), 51-9
DOI 10.1016/j.eplepsyres.2011.02.012, PubMed 21435840

Landmark CJ, Johannessen SI (2011)
Safety aspects of antiepileptic drugs--focus on pharmacovigilance
Pharmacoepidemiol Drug Saf, 21 (1), 11-20
DOI 10.1002/pds.2269, PubMed 22069221

Landmark CJ, Larsson PG, Rytter E, Johannessen SI (2011)
[Clarification about pregabalin and the Norwegian Prescription Database]
Tidsskr Nor Laegeforen, 131 (8), 800-1
DOI 10.4045/tidsskr.11.0292, PubMed 21556068

Publications 2010

Johannessen Landmark C, Patsalos PN (2010)
Drug interactions involving the new second- and third-generation antiepileptic drugs
Expert Rev Neurother, 10 (1), 119-40
DOI 10.1586/ern.09.136, PubMed 20021326

Johannessen SI, Landmark CJ (2010)
Antiepileptic drug interactions - principles and clinical implications
Curr Neuropharmacol, 8 (3), 254-67
DOI 10.2174/157015910792246254, PubMed 21358975

Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ (2010)
Psychiatric comorbidity in patients with epilepsy: a population-based study
Eur J Clin Pharmacol, 66 (11), 1151-60
DOI 10.1007/s00228-010-0861-y, PubMed 20669014

Publications 2009

Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI (2009)
Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions
Epilepsy Res, 87 (1), 31-9
DOI 10.1016/j.eplepsyres.2009.07.005, PubMed 19679449

Rytter E, Landmark CJ, Johannessen SI (2009)
Antiepileptic drug treatment of children at a referral centre for epilepsy--does admission make a difference?
Seizure, 18 (8), 573-9
DOI 10.1016/j.seizure.2009.05.011, PubMed 19576793

Publications 2008

Johannessen Landmark C (2008)
Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy
CNS Drugs, 22 (1), 27-47
DOI 10.2165/00023210-200822010-00003, PubMed 18072813

Johannessen Landmark C, Johannessen SI (2008)
Pharmacological management of epilepsy: recent advances and future prospects
Drugs, 68 (14), 1925-39
DOI 10.2165/00003495-200868140-00001, PubMed 18778117

Johannessen SI, Landmark CJ (2008)
Value of therapeutic drug monitoring in epilepsy
Expert Rev Neurother, 8 (6), 929-39
DOI 10.1586/14737175.8.6.929, PubMed 18505358

Landmark CJ (2008)
Antiepileptic drugs in non-epilepsy disorders - Relations between mechanisms of action and clinical efficacy
CNS Drugs, 22 (1), 27-47

Landmark CJ, Johannessen SI (2008)
Modifications of antiepileptic drugs for improved tolerability and efficacy
Perspect Medicin Chem, 2, 21-39
PubMed 19787095

Landmark CJ, Johannessen SI (2008)
Pharmacological Management of Epilepsy Recent Advances and Future Prospects
Drugs, 68 (14), 1925-1939

Landmark CJ, Patsalos PN (2008)
Interactions between antiepileptic drugs and herbal medicines
Bol. Latinoam. Caribe Plantas M., 7 (2), 108-118

Publications 2007

Landmark CJ, Rytter E, Johannessen SI (2007)
Clinical use of antiepileptic drugs at a referral centre for epilepsy
Seizure, 16 (4), 356-64
DOI 10.1016/j.seizure.2007.02.006, PubMed 17420145

Publications 2006

Landmark CJ (2006)
Targets for antiepileptic drugs in the synapse
Med Sci Monit, 13 (1), RA1-7
PubMed 17179916